Interferon alpha-2b inhalation - Aradigm

Drug Profile

Interferon alpha-2b inhalation - Aradigm

Alternative Names: Inhaled interferon alfa-2b - Aradigm

Latest Information Update: 22 Mar 2007

Price : $50

At a glance

  • Originator Aradigm Corporation
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Hepatitis C

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 22 Mar 2007 Discontinued - Phase-I for Cancer in USA (Inhalation)
  • 22 Mar 2007 Discontinued - Phase-I for Hepatitis C treatment in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top